JP3753761B2 - Phototherapy equipment - Google Patents

Phototherapy equipment Download PDF

Info

Publication number
JP3753761B2
JP3753761B2 JP22098695A JP22098695A JP3753761B2 JP 3753761 B2 JP3753761 B2 JP 3753761B2 JP 22098695 A JP22098695 A JP 22098695A JP 22098695 A JP22098695 A JP 22098695A JP 3753761 B2 JP3753761 B2 JP 3753761B2
Authority
JP
Japan
Prior art keywords
light
blue
jaundice
green
wavelength
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP22098695A
Other languages
Japanese (ja)
Other versions
JPH0938221A (en
Inventor
研正 岡本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purex Corp
Original Assignee
Purex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purex Corp filed Critical Purex Corp
Priority to JP22098695A priority Critical patent/JP3753761B2/en
Publication of JPH0938221A publication Critical patent/JPH0938221A/en
Application granted granted Critical
Publication of JP3753761B2 publication Critical patent/JP3753761B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Landscapes

  • Radiation-Therapy Devices (AREA)

Description

【0001】
【発明の属する技術分野】
本発明は、光線治療装置に関する。さらに詳しくは、病院や医療施設、医療・医学研究機関および研究施設、大学等において黄疸治療を目的として使用する治療置に関するものである。
【0002】
【従来の技術】
黄疸は血液中のビリルビン(bilirubin )という黄色の物質(胆汁色素)によって引き起こされる。この物質は赤血球の溶解の際、血球色素であるヘモグロビンから形成されるが、ビリルビンの生成と肝臓におけるその分解速度の平衡がくずれ、分解の速度が相対的に遅くなって、血液中のビリルビン濃度が高くなった場合に黄疸が生じる。黄疸が最も顕著に現れるのは新生児である。新生児の黄疸は、赤ちゃんの肝臓の中の分解酵素が生後1週間くらいは十分に働かず、血液中のビリルビン濃度が高くなるために起こるとされている。新生児の場合、普通2週間くらいで分解酵素がビリルビンの分解をはじめ、黄疸は消えるが、この分解作用が未発達な未熟児の場合、強い黄疸症状が出ることがある。また、妊娠中において母親と胎児の血液型が不適合の場合にも、重症黄疸をきたすこともある。このような強い黄疸症状は核黄疸と呼ばれ、新生児の大脳をはじめ中枢神経系の障害をもたらし、ひどい場合には脳性マヒや死亡に至ることもある。
このような新生児黄疸の治療方法として、従来より光線治療が用いられている。これは黄疸を起こす色素であるビリルビンが光に分解されやすい物質であり、とくに波長400 から550 ナノメータ(nm)の間の青色、青緑色あるいは緑色の光を皮膚に照射することにより、血中のビリルビン濃度が下がることによる。これは、このような波長の光が、生成直後の水に溶けにくいビリルビン(間接ビリルビン)を水溶性の、つまり血中に溶け込み易い形のビリルビン(直接ビリルビン)に変化させて、肝臓から胆汁とともに腸内に排出され、その後、便や尿に混って体外に排泄されるからである。
光線治療の放射光源としては、上記の波長領域を主成分とする光を放射するものとして、青色ないし青緑色蛍光物質を管内壁に塗布した蛍光管ランプ(蛍光灯)が、従来から現在に至るまで使用されている。図はそのような蛍光灯式新生児黄疸治療保育器を示している。また、高輝度ランプ(ハロゲンランプやキセノンランプ等)に上記の波長領域のみを通過する帯域フィルター(バンドパス・フィルター)をつけ、その出力光を多枝状の光ファイバで取り出して使用するタイプのものもある。
【0003】
【発明が解決しようとする課題】
このような従来型の光線治療用光源の問題点は、蛍光灯ランプ(従来例1)の場合、(1)青色や青緑色の光成分以外に目に有害な紫外線が含まれるので、赤ちゃんの網膜を守るために眼帯をつける必要がある(図参照)、(2)光の強さを自由に変えることができない、(3)ランプ電圧が数十Vと高く感電の危険性がある、(4)ランプが割れる危険性がある、(5)ランプが棒状なので固定された光源としてしか使えない、(6)肌に接して光照射することができない、(7)ランプ自体かなり発熱する、(8)ランプに寿命がある、(9)母親に不安感を与える、などである。
一方、光ファイバを用いる光源(従来例2)の場合、肌に接して光照射することはできるが、(1)光利用効率が悪い、(2)消費電力が大きい、(3)装置そのものが高価、(4)感電の心配はないが光ファイバケーブルそのものが太くて曲がりにくく、使いづらい、などである。
【0004】
本発明は、上記従来例1,2の問題点を全て解消でき、赤ちゃんの網膜を傷付けず、必要な光量を任意に制御でき、効果的かつ簡便な光線治療装置を提供することを目的とする。
【0005】
【課題を解決するための手段
求項1の光線治療装置は、青色から緑色に至る光波長(400nmから550nmまで)領域内の光を発光の中心波長(ピーク波長)とする発光ダイオードを、複数個、衣類に縫い付けて、放射光源としたを特徴とする
請求項2の光線治療装置は、青色から緑色に至る光波長( 400 nmから 550 nmまで)領域内の光を発光の中心波長(ピーク波長)とする発光ダイオードを、複数個、布団に埋め込んで放射光源としており、前記布団は透光性のよい繊維で作られており、光線治療装置の函内に敷かれていることを特徴とする。
【0006】
本発明によれば、黄疸の原因物質である油脂性ビリルビン(間接ビリルビン)を、光化学作用により水溶性のビリルビン(直接ビリルビン)に効率よく変換する波長の光を放つ発光ダイオードを放射光源として用いるので、効果的かつ簡便に黄疸を治療することができる。黄疸治療の場合、黄疸症状の軽重に応じて照射光の強さをコントロールする必要があるが、本発明では発光ダイオードを用いているので、入力電流に比例した光強度が簡単に得られ、照射光制御が簡単にできる。
【0007】
【発明の実施の形態】
発光ダイオード(LED)は、低電圧かつ低電流、小電力で点灯でき、半導体発光素子の代表として、光表示素子(光ディスプレイ)や光通信の光源などに広く用いられている。1980年代のはじめに、光度1カンデラ(cd)を越える超高輝度赤色発光ダイオードが開発され、その後、高輝度化と発光色の短波長化が急速に進んだが、高輝度の青色や青緑色の光を放つ発光ダイオードは製造が非常に難しく、その登場は21世紀になるだろうと思われていた。ところが1993年11月、日亜化学工業(株)は、世界で初めて1cdの超高輝度青色発光ダイオード(発光ピーク波長450 nm)の開発に成功したことを発表した。
この画期的偉業により、従来の青色発光蛍光物質を用いた青色蛍光管(蛍光灯)ランプを青色発光ダイオードで代替することが可能となった。また、同社は1994年4月に発光ピーク波長500 nmの2cd超高輝度青緑色発光ダイオードも発表した。発光ダイオードの応用研究に長年従事している本発明者は、今回、これらの発明記事に着目し、青色ないしは青緑色発光ダイオードを黄疸治療用の光源として利用できることを思いついた。
【0008】
本発明における発光ダイオードを光源として用いる光線治療装置は、黄疸症状の新生児皮膚に青色、青緑色あるいは緑色の光を放射する発光ダイオードの光を照射することにより、皮下のビリルビン濃度を下げ、黄疸を治療することができる。
また、発光ダイオードは、入力電流にほぼ比例した光出力が得られる。図1は、本発明で用いた日亜化学工業製の青緑色青緑色発光ダイオードNLPC500E-490(1個)の入力電流対光照度特性であり、電流と光照度が電流に比例して増大することを示している。したがって、黄疸症状の軽重の程度に応じ、電流値を制御して光強度を調節することが可能である。
さらに、この光線治療装置は、次のような様々な効能を有している。
(1)ビリルビン性黄疸の治療に有効な光波長領域400〜550nm(青色から青緑色を経て緑色まで)の狭波長スペクトルの純色光だけを放射し、紫外線のような目に有害な光線や不要な光、熱線(赤外線)は放射しない。
(2)青色〜緑色発光ダイオードの点灯に必要な電圧は高々3.5 Vであり、発光ダイオードを並列接続する限り感電の心配はない。数ボルトの低電圧で点灯でき、感電の危険性がほとんどない。
(3)電力消費が少くかつ効率がよい。
(4)発光ダイオードは、通常のものでも直径が5mm、長さが8mm程度ないしはそれ以下と小型であり、超高輝度タイプのものでは数mA(ミリ・アンペア)程度のわずかな入力電流できわめて強い光出力が得られる。
(5)発光ダイオードは、板状基板のみならずフレキシブルな基板に多数個取り付けることにより、自由形状でしかも曲げることが可能な面状光源とすることができる。従って、保育器の上蓋に光源を設けた従来型の光線治療器のみならず、帯(ガードル)やガウンなど衣類の形をしたものや、ふとん、マット、敷布などに発光ダイオードを埋め込んだ光線治療具が実現できる。
特許請求の範囲にいう「衣類」とは、ここでいう帯(ガードル)やガウンのほか、後述する腹帯を含む概念である。また、「布団」とは、ここにいうマット、敷布、後述する敷き布団を含む概念である。
(6)発光ダイオードは非常に堅い硬質プラスチックでモールドされており、通常の衝撃ではまず壊れることはない。
【0009
0010】
は青緑色発光ダイオードを腹帯に縫い付けた光線治療装置であり、赤ちゃんの体に巻いて使用する。
【0011】
は青緑色発光ダイオードを敷き布団(マットを含む意味である)に埋め込んだタイプの光線治療装置である。敷き布団は透光性のよい繊維で作られる。
【0012
発明は、新生児黄疸の治療を主たる目的とするものであるが、子供や大人の黄疸治療にも有効である。また、打ち身による内出血や点滴や注射の際に生じる、皮膚の紫色や黄色のあざの治療にも有効である。発光ダイオードを光源として用いる本発明の黄疸光線治療装置は、現在広く使用されている蛍光灯方式の黄疸治療装置に取って変わる可能性があると考えられる。
【0013】
【発明の効果】
本発明の効果は、つぎのとおりである。
( )黄疸の原因物質である油脂性ビリルビン(間接ビリルビン)を、光化学作用により水溶性のビリルビン(直接ビリルビン)に効率よく変換するので、効果的かつ簡便に黄疸を治療することができる。
( )入力電流に比例した光強度が簡単に得られ、照射光制御が簡単にできる。
( )眼に無害である。
( )感電の危険性がない。
( )消費電力が少ない。
( )強い光出力が得られる。
( )光源の形の自由度が高く、種々の形、構成の治療装置を実現できる。
( )破壊しにくく安全である。
【図面の簡単な説明】
【図1】 本発明で用いた日亜化学工業製の青緑色青緑色発光ダイオードNLPC500E-490(1個)の入力電流対光照度特性図である。
【図2】 腹帯に青緑色発光ダイオードを縫い込んだ黄疸光線治療装置の説明図である。
【図3】 ベッドの布団に青緑色発光ダイオードを埋め込んだ黄疸光線治療装置の説明図である。
【図4】 保育器の上蓋に青色蛍光灯を付けた従来型の新生児黄疸光治療装置の説明図である。
[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a phototherapy device. More particularly, hospitals and medical facilities, medical care, medical research institutions and research facilities, it relates to the treatment equipment to be used for the purpose of yellow疸treatment Te universities smell.
[0002]
[Prior art]
Jaundice is caused by a yellow substance (bile pigment) called bilirubin in the blood. This substance is formed from hemoglobin, a blood cell pigment, when red blood cells are lysed, but the balance between the production of bilirubin and its degradation rate in the liver is lost, and the rate of degradation is relatively slow, resulting in the concentration of bilirubin in the blood. Jaundice occurs when becomes high. Jaundice is most noticeable in newborns. Newborn jaundice is said to occur because the degrading enzymes in the baby's liver do not work well for about a week after birth, and the concentration of bilirubin in the blood increases. In the case of a newborn baby, the degrading enzyme usually begins to degrade bilirubin in about 2 weeks, and jaundice disappears. However, in the case of premature infants who have not yet developed this degrading action, strong jaundice may occur. Severe jaundice may also occur during pregnancy if the mother and fetal blood types are incompatible. Such severe jaundice symptoms are called nuclear jaundice, which causes damage to the central nervous system including the cerebrum of the newborn, and in severe cases can lead to cerebral palsy or death.
Conventionally, phototherapy has been used as a treatment method for such newborn jaundice. This is a substance in which bilirubin, a pigment that causes jaundice, is easily decomposed into light. In particular, by irradiating the skin with blue, blue-green, or green light having a wavelength of 400 to 550 nanometers (nm), By lowering bilirubin concentration. This is because light of such a wavelength changes bilirubin (indirect bilirubin), which is difficult to dissolve in water immediately after generation, to water-soluble, that is, a form of bilirubin (direct bilirubin) that is easy to dissolve in the blood, together with bile from the liver It is because it is excreted in the intestine and then mixed with feces and urine to be excreted outside the body.
As a radiation source for phototherapy, a fluorescent tube lamp (fluorescent lamp) in which a blue or blue-green fluorescent material is applied to the inner wall of the tube as a main component that emits light having the above wavelength region as a main component has hitherto been used. Has been used. FIG. 4 shows such a fluorescent-type neonatal jaundice treatment incubator. In addition, a high-intensity lamp (such as a halogen lamp or a xenon lamp) is provided with a bandpass filter (bandpass filter) that passes only the above wavelength region, and the output light is extracted and used with a multi-branch optical fiber. There are also things.
[0003]
[Problems to be solved by the invention]
Problems with such a conventional light treatment light source are that, in the case of a fluorescent lamp (conventional example 1), (1) ultraviolet rays harmful to the eyes are included in addition to the blue and blue-green light components. It is necessary to wear an eye patch to protect the retina (see Fig. 4 ), (2) the intensity of light cannot be changed freely, (3) the lamp voltage is as high as several tens of volts, and there is a risk of electric shock, (4) There is a risk that the lamp will break, (5) The lamp is stick-shaped, so it can only be used as a fixed light source, (6) It cannot irradiate light in contact with the skin, (7) The lamp itself generates considerable heat, (8) The lamp has a lifetime, (9) the mother feels uneasy.
On the other hand, in the case of the light source using the optical fiber (conventional example 2), light can be irradiated in contact with the skin, but (1) the light utilization efficiency is low, (2) the power consumption is large, (3) the device itself is Expensive, (4) There is no worry of electric shock, but the optical fiber cable itself is thick and difficult to bend, making it difficult to use.
[0004]
An object of the present invention is to provide an effective and simple phototherapy device that can eliminate all the problems of the above-mentioned conventional examples 1 and 2, can arbitrarily control the necessary light quantity without damaging the baby's retina. .
[0005]
[Means for Solving the Problems ]
Light beam therapy system Motomeko 1, sewing a light emitting diode for the light in the optical wavelength (from 400nm to 550 nm) region from blue to green and emission center wavelength (peak wavelength), a plurality, clothing It is characterized by a radiation light source.
The phototherapy device according to claim 2, in which a plurality of light emitting diodes having a light emission central wavelength (peak wavelength) within a light wavelength region (from 400 nm to 550 nm) ranging from blue to green are embedded in a futon. As a radiation light source, the futon is made of a light-transmitting fiber and is laid in a box of a phototherapy device.
[0006]
According to the present invention, a light emitting diode that emits light having a wavelength that efficiently converts oily bilirubin (indirect bilirubin), which is a causative agent of jaundice, into water-soluble bilirubin (direct bilirubin) by photochemical action is used as a radiation light source. Jaundice can be treated effectively and simply. In the case of jaundice treatment, it is necessary to control the intensity of irradiation light according to the severity of jaundice symptoms, but since the light emitting diode is used in the present invention, light intensity proportional to the input current can be easily obtained, and irradiation is performed. Easy light control.
[0007]
DETAILED DESCRIPTION OF THE INVENTION
Light-emitting diodes (LEDs) can be lit with low voltage, low current, and low power, and are widely used as optical display elements (optical displays), optical communication light sources, and the like as representative semiconductor light-emitting elements. In the early 1980s, ultra-bright red light emitting diodes with a luminous intensity exceeding 1 candela (cd) were developed. After that, high-brightness and short-wavelengths of luminescent colors progressed rapidly. Light emitting diodes that emit light are very difficult to manufacture, and it was thought that their appearance would be in the 21st century. However, in November 1993, Nichia Corporation announced that it has succeeded in developing the world's first 1 cd ultra-bright blue light-emitting diode (emission peak wavelength 450 nm).
This groundbreaking achievement has made it possible to replace a blue fluorescent tube (fluorescent lamp) lamp using a blue light emitting fluorescent material with a blue light emitting diode. In April 1994, the company also announced a 2cd ultra-bright blue-green light-emitting diode with an emission peak wavelength of 500 nm. The present inventor, who has been engaged in applied research on light emitting diodes for many years, has now focused on these articles and came up with the idea that blue or blue-green light emitting diodes can be used as a light source for treating jaundice.
[0008]
Phototherapy device using the light emitting diode of the present invention as a light source, a blue newborn Kogawa peel jaundice symptoms, by irradiating light from the light emitting diode that emits blue-green or green light, lowering the concentration of bilirubin subcutaneous, Can treat jaundice.
In addition, the light emitting diode can obtain an optical output substantially proportional to the input current. FIG. 1 shows the input current versus light illuminance characteristics of a blue-green blue-green light-emitting diode NLPC500E-490 (1 unit) manufactured by Nichia Corporation used in the present invention. The current and light illuminance increase in proportion to the current. Show. Therefore, it is possible to adjust the light intensity by controlling the current value according to the severity of jaundice symptoms.
Furthermore, this phototherapy device has various effects as follows.
(1) It emits only pure color light with a narrow wavelength spectrum in the light wavelength range of 400 to 550 nm (from blue to blue green to green), which is effective for the treatment of bilirubinous jaundice. Does not radiate light or heat rays (infrared rays).
(2) The voltage required for lighting the blue to green light emitting diodes is 3.5 V at most, and there is no concern of electric shock as long as the light emitting diodes are connected in parallel. It can be lit at a low voltage of several volts and there is almost no risk of electric shock.
(3) Low power consumption and high efficiency.
(4) Light-emitting diodes are small in size with a diameter of 5 mm and a length of about 8 mm or less even with normal ones. Ultra-brightness type diodes are extremely small with a small input current of about several mA (milliampere). Strong light output can be obtained.
(5) By attaching a large number of light emitting diodes to a flexible substrate as well as a plate substrate, a planar light source that can be bent freely can be obtained. Therefore, in addition to conventional phototherapy devices that have a light source on the top lid of the incubator, phototherapy with light-emitting diodes embedded in clothing, such as bands or gowns, futons, mats, and mattresses. A tool can be realized.
The term “clothing” as used in the claims is a concept including an abdominal band described later in addition to a band (girdle) and gown here. The “futon” is a concept including a mat, a mattress, and a mattress described later.
(6) The light emitting diode is molded of a very hard hard plastic and will not be broken by a normal impact.
[0009 ]
[ 0010]
FIG. 2 shows a phototherapy device in which blue-green light emitting diodes are sewn on the abdominal band, and is used by wrapping around a baby's body.
[0011]
FIG. 3 shows a phototherapy device of a type in which a blue-green light emitting diode is embedded and embedded in a futon ( which means that includes a mat ). Futon is made of good fibers translucent.
[0012 ]
The present invention is mainly intended for treating newborn jaundice, but is also effective for treating jaundice in children and adults. It is also effective for treating purple and yellow bruises on the skin caused by internal bleeding caused by bruises, drip, and injection. It is considered that the jaundice light treatment apparatus of the present invention using a light emitting diode as a light source may be replaced with a fluorescent lamp type jaundice treatment apparatus that is currently widely used.
[0013]
【The invention's effect】
The effects of the present invention are as follows.
( 1 ) Since oily bilirubin (indirect bilirubin), which is a causative substance of jaundice, is efficiently converted into water-soluble bilirubin (direct bilirubin) by photochemical action, jaundice can be effectively and easily treated.
( 2 ) Light intensity proportional to the input current can be easily obtained, and irradiation light control can be easily performed.
( 3 ) Harmless to eyes.
( 4 ) There is no risk of electric shock.
( 5 ) Low power consumption.
( 6 ) A strong light output can be obtained.
( 7 ) The degree of freedom of the shape of the light source is high, and treatment devices of various shapes and configurations can be realized.
( 8 ) It is hard to break and safe.
[Brief description of the drawings]
FIG. 1 is a graph showing input current versus light illuminance characteristics of a blue-green-blue-green light-emitting diode NLPC500E-490 (one) manufactured by Nichia Corporation used in the present invention.
FIG. 2 is an explanatory view of a jaundice light treatment device in which blue-green light emitting diodes are sewn into the abdominal band.
FIG. 3 is an explanatory view of a jaundice light treatment apparatus in which a blue-green light emitting diode is embedded in a bed futon.
FIG. 4 is an explanatory view of a conventional neonatal jaundice light treatment apparatus in which a blue fluorescent lamp is attached to the upper lid of the incubator.

Claims (2)

青色から緑色に至る光波長(400nmから550nmまで)領域内の光を発光の中心波長(ピーク波長)とする発光ダイオードを、複数個、衣類に縫い付けて、放射光源とし
ことを特徴とする光線治療装置。
A plurality of light-emitting diodes that emit light in the light wavelength range from blue to green (from 400 nm to 550 nm) with the central wavelength (peak wavelength) of light emitted are sewn on clothing to provide a radiation source .
A phototherapy device characterized by the above .
青色から緑色に至る光波長(  Light wavelength from blue to green ( 400400 nmからfrom nm 550550 nmまで)領域内の光を発光の中心波長(ピーク波長)とする発光ダイオードを、複数個、布団に埋め込んで放射光源としており、(up to nm) A plurality of light emitting diodes with light in the region as the central wavelength (peak wavelength) of light emission are embedded in a futon and used as a radiation light source,
前記布団は透光性のよい繊維で作られており、光線治療装置の函内に敷かれているThe futon is made of translucent fiber and is laid in the box of the phototherapy device
ことを特徴とする光線治療装置。A phototherapy device characterized by the above.
JP22098695A 1995-07-25 1995-07-25 Phototherapy equipment Expired - Fee Related JP3753761B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP22098695A JP3753761B2 (en) 1995-07-25 1995-07-25 Phototherapy equipment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP22098695A JP3753761B2 (en) 1995-07-25 1995-07-25 Phototherapy equipment

Publications (2)

Publication Number Publication Date
JPH0938221A JPH0938221A (en) 1997-02-10
JP3753761B2 true JP3753761B2 (en) 2006-03-08

Family

ID=16759685

Family Applications (1)

Application Number Title Priority Date Filing Date
JP22098695A Expired - Fee Related JP3753761B2 (en) 1995-07-25 1995-07-25 Phototherapy equipment

Country Status (1)

Country Link
JP (1) JP3753761B2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6223071B1 (en) 1998-05-01 2001-04-24 Dusa Pharmaceuticals Inc. Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light
KR20000058582A (en) * 2000-06-16 2000-10-05 김경철 Color cure machine
KR20020048657A (en) * 2000-12-18 2002-06-24 김행석 Apparatus of medical treatment for jaundice using LED
WO2004084892A1 (en) * 2003-03-24 2004-10-07 Abbott Laboratories Use of ritonavir for the treatment of unconjugated hyperbilirubinemia
JP4899040B2 (en) * 2005-07-01 2012-03-21 国立大学法人 岡山大学 Bilirubin denaturator and bilirubin dialysis machine
US8512386B2 (en) * 2007-07-24 2013-08-20 Ric Investments, Llc Infant phototherapy device
WO2014024140A1 (en) * 2012-08-08 2014-02-13 Koninklijke Philips N.V. Led-based phototherapy panel capable of fitting in an x-ray cassette tray of an incubator
CN104548379B (en) * 2014-12-25 2017-08-15 中国科学院苏州生物医学工程技术研究所 A kind of blue green light LED therapeutic instrument for neonatal jaundice
WO2017110194A1 (en) 2015-12-24 2017-06-29 シャープ株式会社 Light irradiating device and phototherapy machine
CN105588043A (en) * 2016-02-23 2016-05-18 天津工业大学 Complex compound eye lens type neonatal jaundice phototherapy illuminating system
CN107823803A (en) * 2017-11-30 2018-03-23 广东彩钦医疗器械有限公司 A kind of Icterus treatment abdominal belt of the red blue light of band
CN110180087A (en) * 2019-06-21 2019-08-30 宁波市妇女儿童医院 A kind of Icterus treatment box
CN113975656B (en) * 2021-12-13 2023-10-13 固安翌光科技有限公司 Phototherapy device for treating neonatal jaundice

Also Published As

Publication number Publication date
JPH0938221A (en) 1997-02-10

Similar Documents

Publication Publication Date Title
JP3753761B2 (en) Phototherapy equipment
US8246666B2 (en) Phototherapy garment
RU2478406C2 (en) Body coating, glasses and/or at least partial head coating, method of irradiation of at least part of human body and use of body coating
CN1250302C (en) Flexible illuminators for phototherapy
US7101384B2 (en) Light processing of selected body components
CN106413810A (en) Method, system and apparatus for non-invasive neurostimulation therapy of the brain
AU2005304736A1 (en) Device and method of phototherapy for jaundiced infants
JP2016518149A (en) Quantum dot light emitting diodes for phototherapy
KR101385707B1 (en) Color therapy system using visible light
WO2018090840A1 (en) Phototherapy device and method for use in metabolic disease
TWI268787B (en) Light therapeutic device
CN201441754U (en) Neonatal jaundice phototherapy blanket
CN107115593A (en) A kind of therapeutic instrument for neonatal jaundice
CN109731231A (en) A kind of even phototherapy pad of combined type low cost
KR100893761B1 (en) A light treatment apparatus for capsule type
CN201328925Y (en) Visual phototherapy instrument
CN102000393A (en) LED (light-emitting diode)-based portable treatment device transmitting 670nm red light
CN109621221A (en) Icterus neonatorum Phototherapeutic instrument
KR20100013650A (en) A light treatment apparatus for rope type
CN202263306U (en) Blue-light LED lampshade and blue-light LED utilizing same of neonatal jaundice therapy apparatus
KR100848391B1 (en) Therapeutic light source and method using the same
KR101630847B1 (en) light module for Photodynamic Therapy
CN206577255U (en) A kind of Phototherapeutic device
CN203154620U (en) Hair growth nursing instrument
KR101705124B1 (en) Light therapy pas

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20041206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20050131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050308

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050415

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20051129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20051214

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101222

Year of fee payment: 5

LAPS Cancellation because of no payment of annual fees